IDH1 and acute myeloid leukemia: Olutasidenib (FT-2102), a brain-penetrant, FDA-approved IDH1 inhibitor, demonstrated a 56% response rate in combination therapy and 38% as monotherapy, with durable responses in relapsed/refractory AML [148–150].